FenaSaúde and the UK’s NICE held a strategic meeting in Brasília to align medical technology assessment practices and ensure greater efficiency in the supplementary healthcare sector.
FenaSaúde recently hosted a high-level dialogue with specialists from the National Institute for Health and Care Excellence (NICE), a renowned institution from the United Kingdom. The central objective of the meeting, held at the Consenso Institute, was to deepen discussions on Health Technology Assessment (HTA) and its impact on the Brazilian market.
The technical exchange focused on overcoming the practical challenges of including innovative treatments, highlighting the urgent need to unite scientific advancements with the economic viability of health plans. The initiative was supported and participated in by leaders from the National Supplementary Health Agency (ANS), Abramge, and British technicians who brought their international experiences to the national scene.
International Cooperation for Innovation
The meeting served as a platform for exchanging methodologies on evidence generation, essential for the assertive and safe incorporation of new therapies. The supplementary healthcare sector currently faces the challenge of absorbing constant innovations without compromising the financial stability of providers and the quality of care for end beneficiaries.
“This technical exchange is crucial for improving our analysis processes in Brazil, always seeking the necessary balance between offering cutting-edge technologies and the financial sustainability of healthcare institutions.”
Future Projections and Impacts
By establishing this bridge with NICE, a global benchmark in cost-effectiveness criteria, FenaSaúde aims to enhance the debate on what should be prioritized in private medical assistance. The expectation is that, based on this knowledge sharing, Brazil will be able to design more robust decision-making models based on global evidence.
The alignment among participating entities reinforces the importance of technical cooperation for the modernization of the system. In the next steps, it is expected that the discussed guidelines will influence future rounds of coverage protocol reviews, placing Brazil at a higher level of scientific rigor and predictability in the medical technology sector.
